

Acknowledgments This trial was supported by The Japanese Foundation for Multidisciplinary Treatment of Cancer. We thank all the members of JFMC34-0601: G. Wakabayashi, Iwate Medical University; H. Bando, Tsukuba University; S. Nakamura, Showa University Hospital; R. Nishimura, Kumamoto City Hospital; S. Amano, Nihon University Itabashi Hospital; T. Ohmura, Sapporo Medical University; Y. Yanagida, Gunma Prefectural Cancer Center; T. Saeki, Saitama Medical University International Medical Center; K. Kojima, Juntendo University Hospital; T. Sawada, Showa University Hospital; H. Ogata, Toho University Omori Medical Center; H. Yasuda, International Medical Center of Japan; S. Takahashi, The Cancer Institute Hospital of JFCR; M. Takami, Tokyo Metropolitan Fuchu Hospital; T. Nishi, Mitsui Memorial Hospital; A. Chiba, Kanagawa Cancer Center; Y. Tokuda, Tokai University; K. Ito, Shinshu University Hospital; T. Utsumi, Fujita Health University; K. Anan, Kitakyushu Municipal Medical Center. We thank Dr. Shigetoyo Saji, Dr. Yoshitaka Furuta, Ms Minako Nakashima and Ms. Kikuko Fujita for their support.

Conflict of interest The authors declare that they have no conflict of interest.

References

- Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. *J Clin Oncol* 15:2483–2493
- Chia S, Swain SM, Byrd DR et al (2008) Locally advanced and inflammatory breast cancer. *J Clin Oncol* 26:786–790
- Makris A, Powles TJ, Ashley SE et al (1998) A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. *Ann Oncol* 9:1179–1184
- Mauriac L, MacGrogan G, Avril A et al (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). *Ann Oncol* 10:47–52
- Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. *J Natl Can Inst* 97:188–194
- Semiglazov VF, Semiglazov VV, Dashyan GA et al (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. *Cancer* 110:244–254
- Ellis MJ, Suman VJ, Hoog J et al (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2–3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. *J Clin Oncol* 29:2342–2349
- Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. *Ann Oncol* 22:1736–1747
- Chang J, Powles TJ, Allred DC et al (2000) Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. *Clin Can Res* 6:616–621
- Miller WR, White S, Dixon JM et al (2006) Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. *Br J Can* 94:1051–1056
- Toi M, Saji S, Masuda N et al (2011) Ki-67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. *Can Sci* 102:858–865
- Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol* 11:55–65
- Mamounas EP, Tang G, Fisher B et al (2010) Association between the 21-gene recurrence score assay and risk of loco-regional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. *J Clin Oncol* 28:1677–1683
- Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *New Engl J Med* 351:2817–2826
- Tang G, Shak S, Paik S et al (2011) Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant! For women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. *Breast Can Res Treat* 127:133–142
- Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol* 24:3726–3734
- National Comprehensive Cancer Network (NCCN) (2013) Clinical practice guidelines in oncology (NCCN®). Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
- Aebi S, Davidson T, Gruber G et al (2011) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 22[Suppl 6: vi]:12–24
- Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol* 25:5287–5312
- Chang JC, Makris A, Gutierrez MC et al (2008) Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. *Breast Can Res Treat* 108:233–240
- Gianni L, Zambetti M, Clark K et al (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. *J Clin Oncol* 23:7265–7277
- Akashi-Tanaka S, Shimizu C, Ando M et al (2009) 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. *Breast* 18:171–174
- Ellis MJ, Ma C (2007) Letrozole in the neoadjuvant setting: the P024 trial. *Breast Can Res Treat* 105[Suppl 1]:33–43
- Kim C, Tang G, Pogue-Geile KL et al (2011) Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. *J Clin Oncol* 29:4160–4167
- Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA* 98:10869–10874
- Dowsett M, Smith IE, Ebbs SR et al (2007) Prognostic value of Ki-67 expression after short-term presurgical endocrine therapy for primary breast cancer. *J Natl Can Inst* 99:167–170
- Ellis MJ, Tao Y, Luo J et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on post neoadjuvant endocrine therapy tumor characteristics. *J Natl Can Inst* 100:1380–1388
- Chia YH, Ellis MJ, Ma CX (2010) Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. *Br J Can* 103:759–764

